Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the company has submitted a new drug application
for omarigliptin, its investigational once-weekly DPP-4 inhibitor for
the treatment of type 2 diabetes, to the Japanese Pharmaceuticals and
Medical Devices Agency (PMDA).
“Merck is committed to helping patients with type 2 diabetes and we are
excited about the submission of the new drug application for
omarigliptin in Japan,” said Peter Stein, M.D., vice president, clinical
research, diabetes and endocrinology, Merck Research Laboratories.
for Merck Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes investment picks